LRMR — Larimar Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $479.94m
- $343.09m
Annual cashflow statement for Larimar Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.6 | -35.4 | -36.9 | -80.6 | -166 |
| Depreciation | |||||
| Non-Cash Items | 5.46 | 5.84 | 5.77 | 3.54 | 5.31 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.75 | 1.62 | -2.59 | 5.99 | 46.8 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -42.1 | -27.6 | -33.5 | -70.8 | -113 |
| Capital Expenditures | -0.333 | -0.1 | -0.164 | -0.515 | -0.091 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 24.5 | -90.9 | 33.5 | -84.9 | 100 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 24.2 | -91 | 33.4 | -85.4 | 100 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 19.9 | 75.3 | 0.03 | 162 | 65.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.95 | -43.3 | -0.076 | 5.74 | 52.2 |